Safety and Efficacy of Liposomal Cytarabine in Combination With Radiotherapy (RT) and Lomustine for the Treatment of Leptomeningeal Metastasis From Malignant Melanoma

Trial Profile

Safety and Efficacy of Liposomal Cytarabine in Combination With Radiotherapy (RT) and Lomustine for the Treatment of Leptomeningeal Metastasis From Malignant Melanoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Cytarabine (Primary) ; Lomustine
  • Indications Carcinomatous meningitis
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Apr 2016 Status changed from recruiting to discontinued as no patients can be recruited for this trial anymore due to other therapeutical approaches that became available.
    • 13 Nov 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 26 Feb 2013 Planned end date changed from 1 Mar 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top